The Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
American Society of Hematology. (2022).
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-azacitidine-for-newly-diagnosed-juvenile-myelomonocytic-leukemia.
American Society of Hematology.
"FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-azacitidine-for-newly-diagnosed-juvenile-myelomonocytic-leukemia
(label-accessed May 10, 2024).
"American Society of Hematology."
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia, 10 May. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2022/fda-approves-azacitidine-for-newly-diagnosed-juvenile-myelomonocytic-leukemia.
